Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19

Lung Cancer. 2021 Nov:161:197-199. doi: 10.1016/j.lungcan.2021.09.018. Epub 2021 Sep 25.

Authors

Cornedine J de Gooijer¹, Vincent van der Noort², Daan van den Broek³, Paul Baas⁴, Jacobus A Burgers⁴

Affiliations

¹ Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: d.d.gooijer@nki.nl.
² Department of Biometrics, Netherlands Cancer Institute Amsterdam, The Netherlands.
³ Department of Laboratory Medicine, Netherlands Cancer Institute Amsterdam, The Netherlands.
⁴ Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

PMID: 34607698
DOI: 10.1016/j.lungcan.2021.09.018

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial

MeSH terms

Antigens, Neoplasm
Biomarkers, Tumor
Humans
Keratin-19
Keratins
Lung Neoplasms* / diagnosis
Lung Neoplasms* / drug therapy
Mesothelioma* / diagnosis
Mesothelioma* / drug therapy
Mesothelioma, Malignant*
Prognosis

Substances

Antigens, Neoplasm
Biomarkers, Tumor
Keratin-19
antigen CYFRA21.1
Keratins